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Abstract The objective of this
study was to investigate the associ-
ation between polymorphisms of
the hypocretin receptor 2 gene
(HCRTR2) and the risk of cluster
headache (CH). The study is a
meta-analysis of published case-
control studies investigating the
association between polymor-
phisms of the HCRTR2 gene and
CH. Pooled odds ratios (OR) were
estimated using both random (RE)
and fixed effects (FE) models.
Three studies, performed in five
different European countries, with
593 cases and 599 controls, were
included in the study. Allele G of
the G1246A HCRTR2 polymor-
phism was significantly associated
with CH (FE OR 1.58, CI 95%
1.27–1.95; RE OR 1.55
(1.14–2.12)). Carriers of the GG
genotype showed a higher disease
risk compared to the remaining
genotypes (FE OR 1.75, CI 95%
1.37–2.25; RE OR 1.69, CI 95%
1.11–2.58). Our data confirm that
the G1246A polymorphism of the
HCRTR2 gene may modulate the
genetic risk for CH. 
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Cluster headache (CH) is one of the most painful types of
primary headaches. The disease consists of attacks of sud-
den, severe, unilateral periorbital pain, accompanied by rest-
lessness and cranial autonomic symptoms, and it is charac-
terised by a strikingly unique circadian and circannual rhyth-
micity [1]. Epidemiological studies have shown a lifetime
disease prevalence rate of approximately 300 cases per
100.000 [2]. A number of recent observations supported a
significant genetic component to CH predisposition: com-
pared with the general population, the first-degree relatives
of CH patients had a 14–39-fold increase in the disease risk
[3–5]. Genetic epidemiological studies, however, suggested
that CH is a complex disease, with several genetic factors
interacting with the environment [6–8]. At present, however,
no molecular genetic clues have been identified for the dis-
ease [8].
The hypocretin receptor 2 gene (HCRTR2) gene is located
on chromosome 6p12.1; it consists of 7 exons and encodes
for a G-protein coupled receptor, exclusively expressed in
the brain [9]. HCRTR2 binds both hypocretin-1 (orexin A)
and hypocretin-2 (orexin B) neuropeptides. The hypocre-
tins/orexin system’s peptides influence a wide range of phys-
iological and behavioural processes in mammals [10, 11].
The involvement of hypocretins in the transmission of pain,
and in autonomic and neuroendocrine functions, may be rel-
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evant for the pathogenesis of CH [12, 13].
We have recently shown that the G1246A polymorphism
of the HCRTR2 gene is significantly associated with CH
[14]. This association was confirmed by a large study per-
formed in Germany, showing that homozygous carriers of
the G allele had a twofold increase in risk for the disease
[15]. On the contrary, the association was not replicated in a
complex dataset of CH patients of Danish, Swedish, and
British origin [16]. 
The aim of the present work was to further evaluate the
association between CH and the HCRTR2 gene. In order to
do so, we performed a meta-analysis of all available studies
that evaluated the association between polymorphisms of the
HCRTR2 gene and the disease. Meta-analysis, a statistical
tool for combining results across studies, is becoming popu-
lar as a method for resolving discrepancies across genetic
association studies. In particular, it is a promising method to
overcome the problem of small sample size and inadequate
statistical power of genetic association studies [17].
Methods 
Selection criteria of studies 
We identified eligible studies by searching Medline for all publica-
tions between January 2004 and December 2006. We used the
search terms “cluster headache”, “association”, and “genetic” in
combination with “orexin”, “hypocretin receptor 2”, “G1246A
polymorphism”, and “HCRTR2 gene”. We included in our meta-
analysis all case-control studies with extractable data. All the
included studies were published as full-length articles or letters in
peer reviewed journals. The diagnosis of CH was made according
to ICHD-II criteria [18]. 
Data extraction
The following data were extracted from each study: first author,
journal, year of publication, ethnicity of study population, genotyp-
ing method, allelic and genotypic frequencies of polymorphism,
diagnosis of subgroups and number of cases and controls. Whereas
they were lacking, we also calculated the allelic and genotypic fre-
quencies of the G1246A polymorphism for cases and controls. Data
were extracted by a single investigator; they were then examined by
two neurologists expert in headaches.
Statistical analysis
We used Review Manager 4.2, a statistical software package for man-
aging and analysing all aspects of a Cochrane Collaboration system-
atic review. The effect of the association was indicated as odds ratio
(OR) with the corresponding 95% confidence interval (CI). We used
both fixed effect (FE) and random effect (RE) to calculate the pooled
OR. RE evaluates the heterogeneity between the studies, and it incor-
porates the between-study variability, representing a more conserva-
tive statistical approach. The heterogeneity between studies was
quantified using the index I2. This index is independent of the num-
ber of studies included in the meta-analysis and takes values between
0 and 100% (I2<25% indicates absence of heterogeneity; I2=25–50%
moderate heterogeneity; I2>50% large heterogeneity). We also used
funnel plot in order to assess small-study bias and publication bias.
We initially compared the frequency of the G allele with the frequen-
cy of A allele. Then we compared GG genotypes with AA genotypes.
Finally, we analysed the dominant (GG vs. GA+AA) and recessive
(GG+GA vs. AA) models for allele G.
Results
Eligible studies
A total of three published articles reported on the relationship
between the G1246A polymorphism (rs2653349) in the
hypocretin receptor 2 gene and CH. All three of these stud-
ies met the inclusion criteria. The study of Baumber et al.
[16] was performed using three different populations, col-
lected in the UK, Sweden and Denmark. So, in the meta-
analysis, the three groups were considered separately (Table
1). All the studies were conducted in Caucasian populations.
The 1246 G/A polymorphism was genotyped using poly-
merase chain reaction (PCR) followed by enzymatic diges-
tion with gel electrophoresis as previously described. The
study of Baumber et al. [16] also investigated the 224.26
A>C polymorphism (rs3122169) of the HCRTR2 gene, but
this polymorphism was not taken into consideration in the
present analysis.
Meta-analysis
The study included 593 CH patients and 599 controls, geno-
typed for the G1246A polymorphism. In all the examined
populations, the allele G was the most frequent for the tested
polymorphism. In all studies, the distribution of the geno-
types in the control groups was in Hardy-Weinberg equilib-
rium (p<0.05). Graphically, we did not find evidence of pub-
lication bias from the funnel plot.
The main analysis investigating the association of the
G1246A allele A and the risk of developing CH relative to the
allele G showed moderate heterogeneity (p=0.11, I2=46.2%)
between the studies. The pooled ORs showed a significant
association with the disease: FE OR: 1.58 (CI 95%
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1.27–1.95) (Fig. 1), RE OR: 1.55 (CI 95% 1.14–2.12). The
dominant model for allele G (GG vs. GA+AA) produced the
same pattern of genotypic association: FE OR: 1.75 (CI 95%
1.37–2.25) (Fig. 2), RE OR: 1.69 (CI 95% 1.11–2.58). There
was no significant statistical difference in any other compari-
son (Table 2).
Discussion
The results of this meta-analysis suggest that genetic varia-
tions of the HCRTR2 gene may influence the risk of CH.
Subjects carrying the G allele or the GG genotype of the stud-
ied polymorphism present a significantly higher risk (OR
1.58–1.75) of developing the disease.
As well as for all meta-analyses, the results of this study
should be considered cautiously. First, the analysis was per-
formed on a relatively small number of retrospective case-
control studies and we cannot exclude the possibility of unde-
tected bias. In addition, all the studies were performed in
Caucasian populations. So, an ethnicity effect may be
involved in this association. Finally, we found a significant
heterogeneity between studies and the presence of population
stratification cannot be excluded. So additional studies in dif-
ferent populations are necessary to confirm these results.
So far, the possible mechanisms underlying the association
between CH and the HCRTR2 gene are unknown. Neurons
Table 1 Distribution of HCRTR2 G1246A polymorphism in CH patients and controls
Distribution of G1246A HCRTR2 polymorphism Frequency of G1246A HCRTR2 alleles
GG GA AA G A
CH patients, Controls, CH patients, Controls, CH patients, Controls, CH patients, Controls, CH patients, Controls,
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Rainero (2004) 103 (94) 163 (77) 4 (4) 43 (20) 2 (2) 5 (3) 210 (96) 369 (87) 8 (4) 53 (13)
Italy
Schurks (2006) 173 (77) 166 (62) 46 (20) 93 (35) 7 (3) 7 (3) 392 (87) 425 (80) 60 (13) 07 (20)
Germany
Baumber (2006) 56 (58) 37 (51) 38 (40) 31 (43) 2 (2) 4 (6) 150 (78) 105 (73) 42 (22) 39 (27)
Denmark
Baumber (2006) 68 (69) 67 (63) 26 (27) 32 (30) 4 (4) 7 (7) 162 (83) 166 (78) 34 (17) 46 (22)
Sweden
Baumber (2006) 41 (65) 57 (64) 20 (32) 2 7 (30) 2 (3) 5 (6) 102 (81) 141 (79) 24 (19) 37 (21)
UK
The corresponding percentages (%) are shown in parentheses
Table 2 Odds ratio and heterogeneity results for the G1246A polymorphism of the HCRTR2 gene in patients with CH
Fixed effects OR (95% CI) Random effects OR (95% CI) I2 (%) p value Q test
Alleles G vs A 1.58 (1.27–1.95) 1.55 (1.14–2.12) 46.2 0.11
Homozygotes GG vs AA 1.57 (0.84–2.92) 1.56 (0.83–2.92) 0 0.88
Dominant model GG vs GA+AA 1.75 (1.37–2.25) 1.69 (1.11–2.58) 59.2 0.04
Recessive model GG+GA vs AA 1.39 (0.75–2.57) 1.38 (0.74–2.57) 0 0.80
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producing hypocretins/orexins are exclusively located in the
lateral hypothalamic area, but project broadly to various
parts of the brain [19]. Hypocretinergic receptors are widely
expressed in the central nervous system, the highest concen-
trations being found in the neocortex, in the hippocampal
formation and in several nuclei of the thalamus, as well as in
many hypothalamic and brainstem structures [20, 21].
Neurons containing hypocretin project to multiple neuronal
systems, including the noradrenergic ascending nucleus, the
serotonergic system of the brainstem, the histaminergic sys-
tem of the hypothalamus and the cholinergic system in the
cerebral cortex [22, 23]. The binding of hypocretins to
HCRTR2 receptors promotes calcium influx within the neu-
rons and exerts a post-synaptic excitatory effect on several
classes of neurons [24, 25]. The G1246A polymorphism of
the HCRTR2 gene is responsible for an aminoacidic substi-
tution (a valine with an isoleucine in position 308) within the
receptor sequence. Our study showed that subjects homozy-
gous for this polymorphism present an increased risk of
developing CH. So, additional studies are needed in order to
elucidate the functional effects of this aminoacidic substitu-
tion on the binding of hypocretins to HCRTR2 receptor and
its possible relevance to CH pathophysiology.
In conclusion, our study confirms the presence of an asso-
ciation between CH and the HCRTR2 gene. This gene may
be considered an important genetic risk factor for the disease.
Furthermore, our data suggest that the hypocretinergic trans-
mission may have a role in the pathophysiology of CH.
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Fig. 1 Meta-analysis for the G1246A polymorphism of the HCRTR2 gene and CH in the comparison between G/G homozygotes vs.
remaining genotypes (G/A+AA) (top) and between carriers of the G and the A allele (bottom). Values are under both fixed (a) and random
(b) effects model. N indicates the total number of participants, n indicates the number of events
Study GG GA+AA OR (fixed) Weight OR (fixed)
or sub-category n/N n/N 95% Cl % 95% Cl
Study G A OR (fixed) Weight OR (fixed)
or sub-category n/N n/N 95% Cl % 95% Cl
Rainero et al. Ita 103/266 6/54 6.39 5.06    [2.09, 12.23]
Baumber et al. Den 56/93 40/75 18.41 1.32    [0.72,   2.45]
Baumber et al. Swe 68/135 30/69 20.59 1.32    [0.74,   2.36]
Baumber et al. UK 41/98 22/54 17.24 1.05    [0.53,   2.06]
Schurks et al. Ger 173/339 53/153 37.37 1.97    [1.32,   2.92]
Total (95% Cl) 931 405 100.00 1.75    [1.37,   2.25]
Total events: 441 (GG), 151 (GA+AA)
Test for heterogeneity: Chi2 = 9.80, df = 4 (P = 0.04), l2 = 59.2%
Test for overail effect: Z = 4.42 (P < 0.0001)
Rainero et al. Ita 210/579 8/61 6.72 3.77    [1.76,   8.08]
Baumber et al. Den 150/255 42/81 19.13 1.33    [0.80,   2.19]
Baumber et al. Swe 162/328 34/80 20.16 1.32    [0.81,   2.16]
Baumber et al. UK 102/243 24/61 16.22 1.12    [0.63,   1.98]
Schurks et al. Ger 392/817 60/167 37.77 1.64    [1.17,   2.32]
Total (95% Cl) 2222 450 100.00 1.58    [1.27,   1.95]
Total events: 1016 (G), 168 (A)
Test for heterogeneity: Chi2 = 7.43, df = 4 (P = 0.11), l2 = 46.2%
Test for overail effect: Z = 4.16 (P < 0.0001)
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